Australia - English - Department of Health (Therapeutic Goods Administration)

paragon care group australia pty ltd trading as immulab - ct876 - thrombophilia and coagulation inhibitor ivds - immucor gti diagnostics ivd kits and reagents are ivds intended to be used for the qualitative screening of coagulation inhibitor- associated antibodies.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - alpha1-proteinase inhibitor 20 mg/ml - solution for injection - 1000 mg/50ml - active: alpha1-proteinase inhibitor 20 mg/ml excipient: monobasic sodium phosphate dihydrate sodium chloride water for injection - chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (a1-pi), also known as alpha1-antitrypsin (aat) deficiency.

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - factor viii, inhibitor bypassing, fraction - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 25 u/ml - antihemorrhagics

Australia - English - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct876 - thrombophilia and coagulation inhibitor ivds - for in vitro diagnostic use in the determination of thrombosis or the abnormal development of clots, and inhibitors of the coagulation process.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - alpha-1-proteinase inhibitor, quantity: 5 g - injection, diluent for - excipient ingredients: - zemaira is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe a1-pi deficiency (a1-pi less than 11 micromolar) and progressive lung disease. patients are to be under optimal pharmacologic and non-pharmacologic treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4 g - injection, diluent for - excipient ingredients: - zemaira is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe a1-pi deficiency (a1-pi less than 11 micromolar) and progressive lung disease. patients are to be under optimal pharmacologic and non-pharmacologic treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct876 - thrombophilia and coagulation inhibitor ivds - ivds that are intended to be used in testing to provide information about thrombosis or the abnormal development of clots, and inhibitors of the coagulation process

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct876 - thrombophilia and coagulation inhibitor ivds - ivds that are intended to be used in testing to provide information about thrombosis or the abnormal development of clots, and inhibitors of the coagulation process

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

africa biosystems tanzania ltd, tanzania - protein transport inhibitor -

Australia - English - Department of Health (Therapeutic Goods Administration)

elitechgroup australia pty ltd - ct876 - thrombophilia and coagulation inhibitor ivds - ivds that are intended to be used in testing to provide information about thrombosis or the abnormal development of clots, and inhibitors of the coagulation process.